Discovery of novel synthetic IL-1 adjuvants

新型合成 IL-1 佐剂的发现

• 批准号: 10027052
• 负责人: JAY EVANS
• 金额: $ 142.57万
• 依托单位: UNIVERSITY OF MONTANA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2020-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10027052
• 关键词: Adaptive Immune System; Adjuvant; Animal Model; Antigens; Award; B-Lymphocytes; Cells; Contractor; FDA approved; Formulation; Human; Immunologic Memory; Innate Immune System; Interleukin-1; Interleukin-1 Receptors; Libraries; Peptide aptamers; Pharmaceutical Chemistry; Preventive vaccine; Research; T-Lymphocyte; Testing; Vaccines; human disease; influenza virus vaccine; novel; pathogen; response; small molecule; synthetic peptide; therapeutic vaccine; vaccine efficacy

The contractor will identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research performed under this award will contribute to the pipeline of new adjuvant leads that either: (a) exploit the natural capacity of the innate immune system to initiate and sustain effective T and B cell responses and to induce long term immune memory, or (b) act directly on cells of the adaptive immune system to enhance their response to pathogen-derived antigens. Studies include testing of adjuvant candidates with experimental or FDA approved preventative or therapeutic vaccines in relevant animal models to determine the potential efficacy of the vaccine against one or more pathogens relevant to human disease.

承包商将确定可用于增强人类疫苗功效的新型候选佐剂。该奖项下进行的研究将有助于开发新的佐剂先导药物：(a) 利用先天免疫系统的自然能力来启动和维持有效的 T 和 B 细胞反应并诱导长期免疫记忆，或 (b) ）直接作用于适应性免疫系统的细胞，增强其对病原体衍生抗原的反应。 研究包括在相关动物模型中使用实验性或 FDA 批准的预防性或治疗性疫苗测试佐剂候选物，以确定疫苗针对与人类疾病相关的一种或多种病原体的潜在功效。